Cardiol Therapeutics announced encouraging results from its Phase II MAvERIC-Pilot study for CardiolRx in symptomatic recurrent pericarditis, presented on November 18, 2024, at the American Heart Association Scientific Sessions 2024. The data demonstrated marked and rapid reductions in both pericarditis pain and inflammation, which were sustained throughout the 26-week study period. These findings provide strong support for advancing CardiolRx into planned Phase III clinical trials.
The study, which enrolled 27 patients, showed a mean pain score reduction of 3.7 points at the primary eight-week endpoint, further improving to 1.5 points by week 26. C-reactive protein levels, a key inflammation marker, normalized in 80% of patients with elevated baseline levels at week 8, with sustained reductions observed. The annualized number of pericarditis episodes significantly decreased from 5.8 prior to the trial to 0.9 during the study.
Furthermore, 71% of participants remained free from recurrence during the extension period after tapering off standard therapies, indicating a durable effect. Treatment with CardiolRx was also shown to be safe and well tolerated in this patient population. These compelling results underscore CardiolRx's potential as a non-immunosuppressive therapy for tens of thousands of pericarditis patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.